{
    "root": "ea730223-414f-4c51-8c91-0935a56a4c01",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tygacil",
    "value": "20250430",
    "ingredients": [
        {
            "name": "TIGECYCLINE",
            "code": "70JE2N95KR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_149836"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        }
    ],
    "indications": {
        "text": "tygacil tetracycline class antibacterial indicated patients 18 years age older : \u2022 complicated skin skin structure infections ( 1.1 ) \u2022 complicated intra-abdominal infections ( 1.2 ) \u2022 community-acquired bacterial pneumonia ( 1.3 ) limitations : tygacil indicated treatment diabetic foot infection hospital-acquired pneumonia , including ventilator-associated pneumonia ( 1.4 ) . reduce development drug-resistant bacteria maintain effectiveness tygacil antibacterial drugs , tygacil used treat infections proven strongly suspected caused bacteria ( 1.5 ) .",
        "doid_entities": [
            {
                "text": "bacterial pneumonia (DOID:874)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_874"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 initial dose 100 mg followed 50 mg every 12 hours administered intravenously approximately 30 60 minutes . ( 2.1 ) \u2022 severe hepatic impairment ( child pugh c ) : initial dose 100 mg followed 25 mg every 12 hours . ( 2.2 ) \u2022 obtain baseline blood coagulation parameters , including fibrinogen , continue monitor regularly treatment tygacil . ( 2.4 , 5.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "tygacil ( tigecycline ) injection supplied single-dose 10 ml glass vial , containing 50 mg tigecycline lyophilized powder reconstitution . supplied : unit sale total content ndc 0008-4994-20 box containing 10 single-dose vials 50 mg/vial",
    "adverseReactions": "tygacil contraindicated patients known hypersensitivity tigecycline excipients . included anaphylactic [ ( 5.3 ) ( 6.2 ) ] .",
    "indications_original": "TYGACIL is a tetracycline class antibacterial indicated in patients 18 years of age and older for: \u2022 Complicated skin and skin structure infections ( 1.1 ) \u2022 Complicated intra-abdominal infections ( 1.2 ) \u2022 Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : TYGACIL is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia ( 1.4 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.5 ).",
    "contraindications_original": "\u2022 Initial dose of 100 mg followed by 50 mg every 12 hours   administered intravenously over approximately 30 to 60 minutes. ( 2.1 ) \u2022 Severe hepatic impairment (Child Pugh   C): Initial dose of 100 mg followed by 25 mg every 12 hours. ( 2.2 ) \u2022 Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with TYGACIL. ( 2.4 , 5.6 )",
    "warningsAndPrecautions_original": "TYGACIL (tigecycline) for injection is supplied in a single-dose 10 mL glass vial, containing 50 mg tigecycline lyophilized powder for reconstitution.\n                  Supplied:\n                  \n                     \n                     \n                     \n                        \n                           \n                              Unit of Sale\n                           \n                           \n                              Total Content\n                           \n                        \n                     \n                     \n                        \n                           \n                              \n                                 NDC 0008-4994-20\n                                 Box containing 10 single-dose vials\n                           \n                           \n                              50 mg/vial",
    "adverseReactions_original": "TYGACIL is contraindicated for use in patients who have known hypersensitivity to tigecycline or to any of the excipients. Reactions have included anaphylactic reactions [see Warnings and Precautions (5.3) and Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Tygacil",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_149836"
        }
    ]
}